Edition:
India

Glenmark Pharmaceuticals Ltd (GLEN.NS)

GLEN.NS on National Stock Exchange of India

306.70INR
11:32am IST
Change (% chg)

Rs7.50 (+2.51%)
Prev Close
Rs299.20
Open
Rs300.00
Day's High
Rs314.80
Day's Low
Rs299.20
Volume
1,502,593
Avg. Vol
1,503,999
52-wk High
Rs705.90
52-wk Low
Rs270.00

Latest Key Developments (Source: Significant Developments)

Glenmark Pharmaceuticals Gets ANDA Approval For Abiraterone Acetate Tablets USP, 250 Mg
Thursday, 17 Oct 2019 

Oct 17 (Reuters) - Glenmark Pharmaceuticals Ltd ::GLENMARK PHARMACEUTICALS LTD SAYS GETS ANDA APPROVAL FOR ABIRATERONE ACETATE TABLETS USP, 250 MG.  Full Article

India's Glenmark Pharmaceuticals June Qtr Consol Net Profit Falls
Tuesday, 13 Aug 2019 

Aug 13 (Reuters) - Glenmark Pharmaceuticals Ltd ::JUNE QUARTER CONSOL NET PROFIT 1.09 BILLION RUPEES VERSUS PROFIT OF 2.33 BILLION RUPEES LAST YEAR.<<>> CONSENSUS FORECAST FOR JUNE QUARTER CONSOL PROFIT WAS 1.82 BILLION RUPEES.JUNE QUARTER CONSOL NET SALES 22.84 BILLION RUPEES VERSUS 21.29 BILLION RUPEES LAST YEAR.OVERALL PERFORMANCE IMPACTED DUE TO MODERATE PERFORMANCE IN U.S. AND SUBDUED PERFORMANCE IN LATAM.  Full Article

Glenmark Pharmaceuticals Ltd Gets ANDA Approval For Solifenacin Succinate Tablets
Tuesday, 21 May 2019 

May 21 (Reuters) - Glenmark Pharmaceuticals Ltd ::RECEIVES ANDA APPROVAL FOR SOLIFENACIN SUCCINATE TABLETS, 5 MG AND 10 MG.  Full Article

India's Glenmark Pharmaceuticals Gets ANDA Approval For Esomeprazole Magnesium Delayed-Release Capsules
Tuesday, 14 May 2019 

May 14 (Reuters) - Glenmark Pharmaceuticals Ltd ::GETS ANDA APPROVAL FOR ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 MG AND 40 MG.  Full Article

Glenmark Pharmaceuticals Ltd Says Its Experimental Rhinitis Treatment Met Main Goal In Phase 3 Study
Wednesday, 8 May 2019 

May 8 (Reuters) - Glenmark Pharmaceuticals Ltd ::GLENMARK PHARMACEUTICALS LTD - K PHARMACEUTICALS ANNOUNCES RESULTS FROM A PHASE 3 STUDY OF RYALTRIS™, AN INVESTIGATIONAL PRODUCT FOR TREATMENT OF SEASONAL ALLERGIC RHINITIS, IN PATIENTS AGED 6 TO UNDER 12 YEARS.GLENMARK PHARMACEUTICALS - STUDY OF RYALTRIS IN PEDIATRIC PATIENTS AGED 6 TO UNDER 12 YEARS OF AGE MET ITS PRIMARY ENDPOINT.GLENMARK PHARMACEUTICALS- RESULTS FROM PHASE 3 STUDY OF RYALTRIS CONSISTENT WITH EXTENSIVE CLINICAL TRIAL EXPERIENCE WITH RYALTRIS IN PATIENTS 12 YRS OF AGE, OLDER.GLENMARK PHARMACEUTICALS LTD - IF APPROVED BY FDA, RYALTRIS WILL BE COMMERCIALIZED BY GLENMARK THERAPEUTICS INC USA.  Full Article

Glenmark Pharmaceuticals Launches Anti‐Diabetes Drug Remogliflozin In India
Tuesday, 30 Apr 2019 

April 30 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS LAUNCHES ANTI‐DIABETES DRUG REMOGLIFLOZIN IN INDIA.  Full Article

Glenmark Pharmaceuticals Gets ANDA Approval For Clindamycin And Benzoyl Peroxide Gel
Friday, 15 Mar 2019 

March 15 (Reuters) - Glenmark Pharmaceuticals Ltd ::GETS ANDA APPROVAL FOR CLINDAMYCIN AND BENZOYL PEROXIDE GEL.  Full Article

Glenmark Pharmaceuticals Gets ANDA Approval For Telmisartan And Hydrochlorothiazide Tablets
Tuesday, 5 Mar 2019 

March 5 (Reuters) - Glenmark Pharmaceuticals Ltd ::GOT ANDA APPROVAL FOR TELMISARTAN AND HYDROCHLOROTHIAZIDE TABLETS USP, 40 MG/12.5 MG, 80 MG/12.5 MG, AND 80 MG/25 MG.  Full Article

Glenmark Pharmaceuticals Gets ANDA Approval For Sevelamer Hydrochloride Tablets
Monday, 11 Feb 2019 

Feb 11 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS RECEIVES ANDA APPROVAL FOR SEVELAMER HYDROCHLORIDE TABLETS, 400 MG AND 800 MG.  Full Article

Glenmark Pharmaceuticals Gets Tentative ANDA Approval For Abiraterone Acetate Tablets USP
Wednesday, 23 Jan 2019 

Jan 23 (Reuters) - Glenmark Pharmaceuticals Ltd ::SAYS GETS TENTATIVE ANDA APPROVAL FOR ABIRATERONE ACETATE TABLETS USP.  Full Article